Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Neuren Pharmaceuticals Limited ( (AU:NEU) ) is now available.
Neuren Pharmaceuticals has initiated the first investigational site in the United States for its Phase 3 clinical trial of NNZ-2591 for Phelan-McDermid syndrome (PMS), marking the first ever Phase 3 trial for this serious neurodevelopmental disorder with no approved treatments. The trial, which is fully funded by Neuren’s existing cash reserves, will assess treatment in approximately 160 children and includes an open-label extension trial. This development highlights Neuren’s commitment to addressing the unmet medical needs in the field of neurodevelopmental disorders and could significantly impact the company’s operations and industry positioning by potentially providing a new treatment option for PMS.
The most recent analyst rating on (AU:NEU) stock is a Buy with a A$22.00 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited is a company focused on developing new drug therapies for serious neurological disorders that emerge in early childhood, which currently have no or limited approved treatment options. The company has received ‘orphan drug’ designation in the United States, which provides incentives for developing therapies for rare and serious diseases. Neuren’s product DAYBUE™ (trofinetide) is approved for the treatment of Rett syndrome, and the company has licensed its development and commercialization to Acadia Pharmaceuticals Inc. Neuren’s second drug candidate, NNZ-2591, is in development for multiple neurodevelopmental disorders.
YTD Price Performance: 37.36%
Average Trading Volume: 496,906
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$2.17B
For an in-depth examination of NEU stock, go to TipRanks’ Overview page.